Stay updated on PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.

Latest updates to the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page
- Check4 days agoChange DetectedAdded Marinesco-Sjögren syndrome and a Genetic and Rare Diseases Information Center resources entry to the page.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision updated to v3.5.0 and removal of v3.4.3.SummaryDifference0.0%

- Check26 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check55 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding lapse notice and Revision: v3.4.1 banner.SummaryDifference0.4%

- Check62 days agoChange DetectedAdded a banner about government funding status and updated the page revision to v3.4.1, replacing the previous v3.4.0 revision note.SummaryDifference0.4%

- Check69 days agoChange DetectedThe page now includes a glossary control and updates several footer/metadata items, including Last Update Submitted that Met QC Criteria, Last Update Posted, capitalization changes to No FEAR Act Data, and the revision noted as v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.